Following its acquisition of Leeman Biotech last year, Pet Pharm Biotech (吉晟生) has announced a massive NT$15 billion investment to build a next-generation radiopharmaceutical facility in Miaoli. Construction is slated to begin in Q2 2026, with production and certification targeted for late 2027.

• Financial Growth: Pet Pharm Biotech reported revenue of NT$220 million in 2025 (+70% YoY). Analysts expect growth to remain above 20% in 2026 as new products and clients are onboarded.
• R&D Pipeline: General Manager Lin Liang-kuang detailed four active projects: two diagnostic agents for Parkinson’s, one tau-protein tracer for Dementia, and a companion diagnostic for a cancer targeted therapy.
• BNCT Ecosystem: Pet Pharm Biotech is collaborating with Heron Neutron Medical (禾榮科) in the Boron Neutron Capture Therapy (BNCT) sector, providing the essential diagnostic tracers required for real-time treatment monitoring.
• Strategic Vision: Chairman Yang Chao-tang noted that the Miaoli plant will produce radioisotope raw materials for export to South Korea and Southeast Asia, and the company is already evaluating a fourth manufacturing site.

Resource: 搶攻核醫藥市場！吉晟生繼去年併購禮曼生技後 再投資15億打造苗栗新廠